Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.
about
Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015.Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age.Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive diseaseKaiser Permanente Vaccine Study Center: Highlights of 2009-2012.Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infantsDevelopment of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X.MenACWY-TT vaccine for active immunization against invasive meningococcal disease.Meningococcal disease: changes in epidemiology and prevention.Fighting Neisseria meningitidis: past and current vaccination strategies.Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia.Peptide adjacent to glycosylation sites impacts immunogenicity of glycoconjugate vaccine.
P2860
Q33168344-3413D3F3-35AE-4C02-8A9A-7EF5C221A6FCQ34290891-EA46BA39-F61A-4725-B21A-F40888C90C95Q35187182-CF432C75-C2E5-4577-9386-379BC1AAFA8FQ35890630-8035A30F-B7A9-4F76-BABD-4A21262B04C8Q37131083-ED2AB169-1376-4FDD-AF76-5C5B9885ABF9Q37340824-29F1168A-CEA0-43FC-B2AA-E31938265FBAQ38028992-7E08DCFC-EF59-437E-B3BE-BA80295B17BDQ38052545-23362747-A057-4A1A-BFC4-FEDE79FC8452Q38829564-0E0915CA-BA8D-4DA7-A975-F6464EAA9A17Q41648169-EE94F0C4-F499-498D-B963-6259BE51D088Q50076098-C3B21203-38B3-43F0-9024-0F60EAEE0291
P2860
Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Comparison of the safety and i ...... in children 2-10 years of age.
@en
type
label
Comparison of the safety and i ...... in children 2-10 years of age.
@en
prefLabel
Comparison of the safety and i ...... in children 2-10 years of age.
@en
P2093
P50
P1433
P1476
Comparison of the safety and i ...... in children 2-10 years of age.
@en
P2093
Anil Gupta
Emmanuel Walter
Keith Reisinger
Lisa Bedell
Peter M Dull
Robert Jeanfreau
P304
P356
10.1016/J.VACCINE.2010.09.092
P407
P577
2010-10-29T00:00:00Z